Nash Huw M.
Known title: COO & CBOCIK: 0001780085
Associated companies
Transaction History
| STOK | ▼ Sell | Open Market | 2,467 | $32K | 7/2/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 33 | $459 | 7/2/2024 | View on chart |
| STOK | ▲ Buy | Option Exercise | 50,000 | $20K | 5/20/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 50,000 | $770K | 5/20/2024 | View on chart |
| STOK | ▲ Buy | Option Exercise | 50,000 | $20K | 4/1/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 60,929 | $806K | 4/1/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 400 | $5K | 4/1/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 4,116 | $25K | 3/19/2024 | View on chart |
| STOK | ▲ Buy | Option Exercise | 13,100 | $0 | 3/15/2024 | View on chart |
| STOK | ▼ Sell | Open Market | 200 | $5K | 1/3/2022 | View on chart |
| STOK | ▼ Sell | Open Market | 2,103 | $49K | 1/3/2022 | View on chart |
| STOK | ▲ Buy | Option Exercise | 3,800 | $8K | 1/3/2022 | View on chart |
| STOK | ▼ Sell | Open Market | 1,497 | $34K | 1/3/2022 | View on chart |
| STOK | ▲ Buy | Option Exercise | 5,700 | $12K | 12/1/2021 | View on chart |
| STOK | ▼ Sell | Open Market | 3,200 | $77K | 12/1/2021 | View on chart |
| STOK | ▼ Sell | Open Market | 2,500 | $63K | 12/1/2021 | View on chart |
| STOK | ▲ Buy | Option Exercise | 1,900 | $4K | 11/3/2021 | View on chart |
| STOK | ▼ Sell | Open Market | 1,900 | $48K | 11/3/2021 | View on chart |
| STOK | ▲ Buy | Option Exercise | 3,800 | $8K | 11/1/2021 | View on chart |
| STOK | ▼ Sell | Open Market | 2,190 | $51K | 11/1/2021 | View on chart |
| STOK | ▼ Sell | Open Market | 1,610 | $38K | 11/1/2021 | View on chart |
| STOK | ▲ Buy | Option Exercise | 5,700 | $12K | 10/1/2021 | View on chart |
| STOK | ▼ Sell | Open Market | 5,700 | $142K | 10/1/2021 | View on chart |
| STOK | ▲ Buy | Option Exercise | 5,700 | $12K | 9/1/2021 | View on chart |
| STOK | ▼ Sell | Open Market | 5,700 | $148K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting
Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.
Stoke Therapeutics presents STK-002 data at AAO 2026 meeting. Stoke Therapeutics presented new data on its investigational drug STK-002 at the American Academy of Ophthalmology 2026 annual meeting. The data suggest the therapy may have disease-modifying potential for autosomal dominant optic atrophy. In a separate update, the company noted FDA alignment on endpoint criteria for its Zorevunersen program, which could affect future trial design.